A Phase 2 Multicenter, Single Dose, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Evaluating the Safety and Efficacy of Two Doses of Stannsoporfin in Combination With Phototherapy in Neonates
Phase of Trial: Phase II
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs Stannsoporfin (Primary)
- Indications Neonatal jaundice
- Focus Therapeutic Use
- Acronyms Jasmine; JASMINE_204
- Sponsors InfaCare Pharmaceutical Corporation
- 25 Mar 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 15 Jan 2016 Planned primary completion date changed from 1 Jul 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov.
- 26 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 Jul 2015 as reported by ClinicalTrials.gov.